2016 ESC/EAS guidelines for the management of dyslipidaemias AL Catapano, I Graham, G De Backer, O Wiklund, MJ Chapman, H Drexel, ... European heart journal 37 (39), 2999-3058, 2016 | 4899 | 2016 |
2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the … V Regitz-Zagrosek, JW Roos-Hesselink, J Bauersachs, ... European heart journal 39 (34), 3165-3241, 2018 | 4240 | 2018 |
European Society of Cardiology: cardiovascular disease statistics 2019 A Timmis, N Townsend, CP Gale, A Torbica, M Lettino, SE Petersen, ... European heart journal 41 (1), 12-85, 2020 | 3175 | 2020 |
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management … Authors/Task Force Members, SD Kristensen, J Knuuti, A Saraste, ... European heart journal 35 (35), 2383-2431, 2014 | 2379 | 2014 |
Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2253 | 2015 |
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients … N Marx, M Federici, K Schütt, D Müller-Wieland, RA Ajjan, MJ Antunes, ... European heart journal 44 (39), 4043-4140, 2023 | 747 | 2023 |
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial AA Voors, CE Angermann, JR Teerlink, SP Collins, M Kosiborod, J Biegus, ... Nature medicine 28 (3), 568-574, 2022 | 713 | 2022 |
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study KK Ray, B Molemans, WM Schoonen, P Giovas, S Bray, G Kiru, J Murphy, ... European journal of preventive cardiology 28 (11), 1279-1289, 2021 | 711 | 2021 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label … D Sibbing, D Aradi, C Jacobshagen, L Gross, D Trenk, T Geisler, M Orban, ... The Lancet 390 (10104), 1747-1757, 2017 | 613 | 2017 |
Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries SD Kristensen, KG Laut, J Fajadet, Z Kaifoszova, P Kala, C Di Mario, ... European heart journal 35 (29), 1957-1970, 2014 | 521 | 2014 |
6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial M Gilard, P Barragan, AAL Noryani, HA Noor, T Majwal, T Hovasse, ... Journal of the American College of Cardiology 65 (8), 777-786, 2015 | 433 | 2015 |
Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial TA Zelniker, MP Bonaca, RHM Furtado, O Mosenzon, JF Kuder, ... Circulation 141 (15), 1227-1234, 2020 | 399 | 2020 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention D Aradi, RF Storey, A Komócsi, D Trenk, D Gulba, RG Kiss, S Husted, ... European heart journal 35 (4), 209-215, 2014 | 366 | 2014 |
Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial ET Kato, RP Giugliano, CT Ruff, Y Koretsune, T Yamashita, RG Kiss, ... Journal of the American Heart Association 5 (5), e003432, 2016 | 328 | 2016 |
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 288 | 2019 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind … EM Ohman, MT Roe, PG Steg, SK James, TJ Povsic, J White, F Rockhold, ... The Lancet 389 (10081), 1799-1808, 2017 | 244 | 2017 |
Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial ML O’Donoghue, R Glaser, MA Cavender, PE Aylward, MP Bonaca, ... Jama 315 (15), 1591-1599, 2016 | 243 | 2016 |
Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ... Journal of the American College of Cardiology 73 (4), 387-396, 2019 | 210 | 2019 |
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial MS Sabatine, EM Antman, P Widimsky, IO Ebrahim, RG Kiss, A Saaiman, ... The Lancet 374 (9692), 787-795, 2009 | 190 | 2009 |
Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study M Gyöngyösi, I Lang, M Dettke, G Beran, S Graf, H Sochor, N Nyolczas, ... Nature Clinical Practice Cardiovascular Medicine 6 (1), 70-81, 2009 | 178 | 2009 |